CRISPR technologies for the treatment of Duchenne muscular dystrophy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CRISPR technologies for the treatment of Duchenne muscular dystrophy
Authors
Keywords
CRISPR, Cas, Duchenne muscular dystrophy, genome editing, neuromuscular disorder
Journal
MOLECULAR THERAPY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-04-04
DOI
10.1016/j.ymthe.2021.04.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Golodirsen: First Approval
- (2020) Young-A Heo DRUGS
- Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
- (2020) Diane E. Frank et al. NEUROLOGY
- Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy
- (2020) Sara Mata López et al. PLoS One
- Expanding the genome-targeting scope and the site selectivity of high-precision base editors
- (2020) Junjie Tan et al. Nature Communications
- High-throughput identification of post-transcriptional utrophin up-regulators for Duchenne muscle dystrophy (DMD) therapy
- (2020) Emanuele Loro et al. Scientific Reports
- Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system
- (2020) Yu Zhang et al. Science Advances
- Improvement of muscular atrophy by AAV–SaCas9-mediated myostatin gene editing in aged mice
- (2020) Shaoting Weng et al. CANCER GENE THERAPY
- Correction of three prominent mutations in mouse and human models of Duchenne muscular dystrophy by single-cut genome editing
- (2020) Yi-Li Min et al. MOLECULAR THERAPY
- Directed evolution of adenine base editors with increased activity and therapeutic application
- (2020) Nicole M. Gaudelli et al. NATURE BIOTECHNOLOGY
- A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope
- (2020) Ziying Hu et al. PLOS BIOLOGY
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
- (2020) Paula R. Clemens et al. JAMA Neurology
- Myostatin inhibition promotes fast fibre hypertrophy but causes loss of AMP‐activated protein kinase signalling and poor exercise tolerance in a model of limb‐girdle muscular dystrophy R1/2A
- (2020) Irina Kramerova et al. JOURNAL OF PHYSIOLOGY-LONDON
- Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice
- (2020) Anne Forand et al. Molecular Therapy-Methods & Clinical Development
- Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model
- (2020) Alper Yavas et al. PLoS One
- Genome Editing-Mediated Utrophin Upregulation in Duchenne Muscular Dystrophy Stem Cells
- (2020) Kasturi Sengupta et al. Molecular Therapy-Nucleic Acids
- The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle
- (2020) Emma Rybalka et al. Cells
- CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells
- (2019) Yi-Li Min et al. Science Advances
- Identification of preexisting adaptive immunity to Cas9 proteins in humans
- (2019) Carsten T. Charlesworth et al. NATURE MEDICINE
- Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
- (2019) Christopher E. Nelson et al. NATURE MEDICINE
- Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
- (2019) Benjamin P. Kleinstiver et al. NATURE BIOTECHNOLOGY
- The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
- (2019) Simon Guiraud et al. HUMAN MOLECULAR GENETICS
- CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene
- (2019) Tatiana V. Egorova et al. Disease Models & Mechanisms
- Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors
- (2019) Tony P. Huang et al. NATURE BIOTECHNOLOGY
- Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy
- (2019) Aojie Cai et al. Human Gene Therapy Methods
- AAV-based gene therapies for the muscular dystrophies
- (2019) Julie M Crudele et al. HUMAN MOLECULAR GENETICS
- Efficient base editing for multiple genes and loci in pigs using base editors
- (2019) Jingke Xie et al. Nature Communications
- Search-and-replace genome editing without double-strand breaks or donor DNA
- (2019) Andrew V. Anzalone et al. NATURE
- Expanding C–T base editing toolkit with diversified cytidine deaminases
- (2019) Tian-Lin Cheng et al. Nature Communications
- In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse
- (2019) Leonela Amoasii et al. Nature Communications
- Efficient base editing with expanded targeting scope using an engineered Spy-mac Cas9 variant
- (2019) Zhiquan Liu et al. Cell Discovery
- A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9
- (2018) Tingting Sui et al. Disease Models & Mechanisms
- CRISPR RNAs trigger innate immune responses in human cells
- (2018) Sojung Kim et al. GENOME RESEARCH
- Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
- (2018) Christian Hinderer et al. HUMAN GENE THERAPY
- Severe Toxicity in Nonhuman Primates and Piglets with Systemic High-Dose Administration of Adeno-Associated Virus Serotype 9–Like Vectors: Putting Patients First
- (2018) Terence R. Flotte et al. HUMAN GENE THERAPY
- Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9
- (2018) Taeyoung Koo et al. MOLECULAR THERAPY
- Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy
- (2018) Seuk-Min Ryu et al. NATURE BIOTECHNOLOGY
- Base editing with a Cpf1–cytidine deaminase fusion
- (2018) Xiaosa Li et al. NATURE BIOTECHNOLOGY
- A highly specific SpCas9 variant is identified by in vivo screening in yeast
- (2018) Antonio Casini et al. NATURE BIOTECHNOLOGY
- Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
- (2018) Hirofumi Komaki et al. Science Translational Medicine
- Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing
- (2018) Chengzu Long et al. Science Advances
- CRISPR/Cas9-mediated sheep MSTN gene knockout and promote sSMSCs differentiation
- (2018) Yani Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Evolved Cas9 variants with broad PAM compatibility and high DNA specificity
- (2018) Johnny H. Hu et al. NATURE
- Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
- (2018) Leonela Amoasii et al. SCIENCE
- Engineered CRISPR-Cas9 nuclease with expanded targeting space
- (2018) Hiroshi Nishimasu et al. SCIENCE
- Genetic Modulation of RNA Splicing with a CRISPR-Guided Cytidine Deaminase
- (2018) Juanjuan Yuan et al. MOLECULAR CELL
- CRISPR-offinder: a CRISPR guide RNA design and off-target searching tool for user-defined protospacer adjacent motif
- (2017) Changzhi Zhao et al. International Journal of Biological Sciences
- Enhanced proofreading governs CRISPR–Cas9 targeting accuracy
- (2017) Janice S. Chen et al. NATURE
- Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
- (2017) Nicole M. Gaudelli et al. NATURE
- Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions
- (2017) Y Bill Kim et al. NATURE BIOTECHNOLOGY
- Highly efficient RNA-guided base editing in mouse embryos
- (2017) Kyoungmi Kim et al. NATURE BIOTECHNOLOGY
- CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets
- (2017) Shengdar Q Tsai et al. NATURE METHODS
- Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy
- (2017) Leonela Amoasii et al. Science Translational Medicine
- In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni
- (2017) Eunji Kim et al. Nature Communications
- Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
- (2017) Niclas E. Bengtsson et al. Nature Communications
- CRISPR/Cas9-Mediated Genome Editing Corrects Dystrophin Mutation in Skeletal Muscle Stem Cells in a Mouse Model of Muscle Dystrophy
- (2017) Pei Zhu et al. Molecular Therapy-Nucleic Acids
- Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160
- (2017) Arnaud Perrin et al. Molecular Therapy-Nucleic Acids
- CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice
- (2017) Yu Zhang et al. Science Advances
- Correction: CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool
- (2017) Manuel Stemmer et al. PLoS One
- Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders
- (2016) Daria Wojtal et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Cpf1 nucleases demonstrate robust activity to induce DNA modification by exploiting homology directed repair pathways in mammalian cells
- (2016) Eszter Tóth et al. Biology Direct
- A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells
- (2016) Courtney S. Young et al. Cell Stem Cell
- CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy
- (2016) Charis L Himeda et al. MOLECULAR THERAPY
- Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
- (2016) Alexis C. Komor et al. NATURE
- High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects
- (2016) Benjamin P. Kleinstiver et al. NATURE
- Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells
- (2016) Yunqing Ma et al. NATURE METHODS
- Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations
- (2016) Ignazio Maggio et al. NUCLEIC ACIDS RESEARCH
- CT-Finder: A Web Service for CRISPR Optimal Target Prediction and Visualization
- (2016) Houxiang Zhu et al. Scientific Reports
- Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells
- (2016) Ignazio Maggio et al. Scientific Reports
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
- (2015) Bernd Zetsche et al. CELL
- Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9
- (2015) Yongchang Chen et al. HUMAN MOLECULAR GENETICS
- The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
- (2015) Catherine L. Bladen et al. HUMAN MUTATION
- In vivo genome editing using Staphylococcus aureus Cas9
- (2015) F. Ann Ran et al. NATURE
- Highly efficient Cas9-mediated transcriptional programming
- (2015) Alejandro Chavez et al. NATURE METHODS
- Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells
- (2015) Daesik Kim et al. NATURE METHODS
- Muscle wasting in disease: molecular mechanisms and promising therapies
- (2015) Shenhav Cohen et al. NATURE REVIEWS DRUG DISCOVERY
- Rationally engineered Cas9 nucleases with improved specificity
- (2015) I. M. Slaymaker et al. SCIENCE
- Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy
- (2015) C. Long et al. SCIENCE
- In vivo gene editing in dystrophic mouse muscle and muscle stem cells
- (2015) M. Tabebordbar et al. SCIENCE
- In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
- (2015) C. E. Nelson et al. SCIENCE
- Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy
- (2015) David G. Ousterout et al. Nature Communications
- Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9
- (2015) Hongmei Lisa Li et al. Stem Cell Reports
- Low dystrophin levels in heart can delay heart failure in mdx mice
- (2014) Maaike van Putten et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
- (2014) Yanfang Fu et al. NATURE BIOTECHNOLOGY
- GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
- (2014) Shengdar Q Tsai et al. NATURE BIOTECHNOLOGY
- Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA
- (2014) C. Long et al. SCIENCE
- Comparison of non-canonical PAMs for CRISPR/Cas9-mediated DNA cleavage in human cells
- (2014) Yilan Zhang et al. Scientific Reports
- Generation of muscular dystrophy model rats with a CRISPR/Cas system
- (2014) Katsuyuki Nakamura et al. Scientific Reports
- Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system
- (2013) Albert W Cheng et al. CELL RESEARCH
- Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice
- (2013) Maaike van Putten et al. FASEB JOURNAL
- Nonhuman Primate Models in the Genomic Era: A Paradigm Shift
- (2013) E. J. Vallender et al. ILAR JOURNAL
- DNA targeting specificity of RNA-guided Cas9 nucleases
- (2013) Patrick D Hsu et al. NATURE BIOTECHNOLOGY
- RNA-guided gene activation by CRISPR-Cas9–based transcription factors
- (2013) Pablo Perez-Pinera et al. NATURE METHODS
- CRISPR interference (CRISPRi) for sequence-specific control of gene expression
- (2013) Matthew H Larson et al. Nature Protocols
- A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
- (2012) M. Jinek et al. SCIENCE
- Double-Strand Break End Resection and Repair Pathway Choice
- (2011) Lorraine S. Symington et al. Annual Review of Genetics
- Marginal Level Dystrophin Expression Improves Clinical Outcome in a Strain of Dystrophin/Utrophin Double Knockout Mice
- (2010) Dejia Li et al. PLoS One
- Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations
- (2009) Annemieke Aartsma-Rus et al. HUMAN MUTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now